Literature DB >> 21556869

Head tremor secondary to MS resolved with rituximab.

Chakorn Chansakul1, Guillermo Moguel-Cobos, Roberto Bomprezzi.   

Abstract

We describe the case of a 33-year-old woman who presented with a 2-month history of worsening head tremor. The medical evaluation led to the new diagnosis of MS and the MRI of brain demonstrated prominently active disease. Intravenous rituximab was started according to the HERMES trial, and significant improvement was noted. She has received additional rituximab dosing approximately every 6 months, and at the 2-year follow-up the tremor has not recurred. The resolution of head tremor likely resulted from the complete suppression of MS disease activity, which must have allowed restoration of normal neural circuitry. In agreement with a growing body of evidence that supports early control of MS disease activity to prevent accumulation of fixed disability, this case advocates for aggressive immunological therapy at the onset of tremor in MS patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21556869     DOI: 10.1007/s10072-011-0600-x

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  14 in total

Review 1.  Animal models of tremor.

Authors:  H Wilms; J Sievers; G Deuschl
Journal:  Mov Disord       Date:  1999-07       Impact factor: 10.338

Review 2.  The pathophysiology of tremor.

Authors:  G Deuschl; J Raethjen; M Lindemann; P Krack
Journal:  Muscle Nerve       Date:  2001-06       Impact factor: 3.217

3.  Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor.

Authors:  G P Rice; J Lesaux; P Vandervoort; L Macewan; G C Ebers
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

4.  A study of tremor in multiple sclerosis.

Authors:  S H Alusi; J Worthington; S Glickman; P G Bain
Journal:  Brain       Date:  2001-04       Impact factor: 13.501

5.  Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report.

Authors:  Nirit Weiss; Richard B North; Shinji Ohara; Frederick A Lenz
Journal:  J Neurosurg       Date:  2003-10       Impact factor: 5.115

6.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors:  Stephen L Hauser; Emmanuelle Waubant; Douglas L Arnold; Timothy Vollmer; Jack Antel; Robert J Fox; Amit Bar-Or; Michael Panzara; Neena Sarkar; Sunil Agarwal; Annette Langer-Gould; Craig H Smith
Journal:  N Engl J Med       Date:  2008-02-14       Impact factor: 91.245

7.  Early relapses after the first dose of natalizumab in active multiple sclerosis patients.

Authors:  D Centonze; R Furlan; C Gasperini; M Salvetti; L Battistini
Journal:  Mult Scler       Date:  2008-08-13       Impact factor: 6.312

8.  Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.

Authors:  G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi
Journal:  Lancet       Date:  2009-10-06       Impact factor: 79.321

Review 9.  Movement disorders in multiple sclerosis.

Authors:  C Tranchant; K P Bhatia; C D Marsden
Journal:  Mov Disord       Date:  1995-07       Impact factor: 10.338

10.  Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes.

Authors:  L Kappos; C H Polman; M S Freedman; G Edan; H P Hartung; D H Miller; X Montalban; F Barkhof; L Bauer; P Jakobs; C Pohl; R Sandbrink
Journal:  Neurology       Date:  2006-08-16       Impact factor: 9.910

View more
  2 in total

1.  Head tremor at disease onset: an ataxic phenotype of cervical dystonia.

Authors:  Aristide Merola; Alok K Dwivedi; Aasef G Shaikh; Tamour Khan Tareen; Gustavo A Da Prat; Marcelo A Kauffman; Jennie Hampf; Abhimanyu Mahajan; Luca Marsili; Joseph Jankovic; Cynthia L Comella; Brian D Berman; Joel S Perlmutter; Hyder A Jinnah; Alberto J Espay
Journal:  J Neurol       Date:  2019-04-26       Impact factor: 4.849

2.  Understanding tremor in multiple sclerosis: prevalence, pathological anatomy, and pharmacological and surgical approaches to treatment.

Authors:  Andrés Labiano-Fontcuberta; Julián Benito-León
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2012-09-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.